Nuvectra (OTCMKTS:NVTRQ) versus T2 Biosystems (NASDAQ:TTOO) Critical Comparison

Nuvectra (OTCMKTS: NVTRQ – Get Rating) and T2 Biosystems (NASDAQ: TTOO – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.


This table compares the net margins, return on equity and return on assets of Nuvectra and T2 Biosystems.

Net margins Return on equity return on assets
Nuvectra N / A N / A N / A
T2 Biosystems -194.37% -1,278.55% -85.22%

Institutional and Insider Ownership

11.2% of the shares of T2 Biosystems are held by institutional investors. 2.9% of Nuvectra shares are held by insiders. Comparatively, 6.9% of T2 Biosystems shares are held by insiders. Strong institutional ownership indicates that large money managers, endowments, and hedge funds believe a stock will outperform the market over the long term.

Benefits and evaluation

This table compares the revenue, earnings per share and valuation of Nuvectra and T2 Biosystems.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Nuvectra N / A N / A N / A N / A N / A
T2 Biosystems $28.06 million 0.91 -$49.24 million ($0.33) -0.45

Nuvectra has higher revenues, but lower revenues than T2 Biosystems.

Analyst Recommendations

This is a summary of current ratings and recommendations for Nuvectra and T2 Biosystems, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Nuvectra 0 0 0 0 N / A
T2 Biosystems 0 0 2 0 3.00

T2 Biosystems has a consensus target price of $1.10, suggesting a potential upside of 633.33%. Given the higher possible upside of T2 Biosystems, analysts clearly believe that T2 Biosystems is more favorable than Nuvectra.


T2 Biosystems beats Nuvectra on 5 of the 8 factors compared between the two stocks.

Nuvectra Company Profile (Get an evaluation)

Nuvectra Corporation, a neurostimulation medical device company, develops and markets a neurostimulation technology platform for the treatment of various disorders in the neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable trunk and limb pain. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson’s disease. The company serves hospitals, surgery centers and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.

T2 Biosystems Company Profile (Get an evaluation)

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables the detection of pathogens, biomarkers and other abnormalities in various types of unpurified patient samples, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid and urine. The company also offers T2Dx Instrument, a benchtop instrument that runs various diagnostic tests from patient samples; T2Candida, a direct blood test that identifies blood infections that cause sepsis and candidemia; T2Bacteria, a direct blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. Additionally, he is developing T2Biothreat for the detection of bio-threat pathogens; comprehensive sepsis panel to detect blood infections caused by bacterial species and Candida, and antibiotic resistance markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood and hospital environmental samples; and T2Lyme, a direct blood test panel designed to work on the T2Dx instrument to identify bacteria that cause Lyme disease. The company has collaborative agreements with Canon US Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Get news and reviews for Nuvectra Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Nuvectra and related companies with’s FREE daily newsletter.